Various strategies to limit the microenvironment-leukemia crosstalk have been investigated i.e., CXCR4/CXCL12 inhibitors (74, 86), TGF-β neutralizing antibodies (87), and blockage of IL-6 with mAbs (88). The gene discussed is TGFB1; the disease is leukemia.